



Sheet 1 of 2

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 2543-1-033
		SERIAL NO. 10/736,227
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Jonathan A. Terrett
		FILING DATE December 15, 2003
		GROUP Unknown 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB- CLASS	TRANSLATION. YES NO
amh	BA	WO 01/13117A2 & A3 (EP 1208381)	2/22/01	PCT			
✓	BB	WO 00/55628 (EP 1159618)	9/21/00	PCT			
✓	BC	WO 02/64611	8/22/02	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

amh	CA	Baselga, J., et al., Recombinant Humanized Anti-HER2 Antibody(Herceptin™)Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts', 1998, Cancer Res. 58: 2825-2831
✓	CB	Catimel, B., et al., Purification and Characterization of a Novel Restricted Antigen Expressed by Normal and Transformed Human Colonic Epithelium,1996, J. Biol. Chem. 271:25664-25670
✓	CC	ABSTRACT for Craggs, et al., 2003, Applied Genomics & Proteomics 2(2):101-100
✓	CD	Davis, ID,et al.,An overview of Cancer immunotherapy,2000, Immunol Cell Biol. 78: 179-196
✓	CE	Dillman, R.O.,Perceptions of Herceptin®:A Monoclonal Antibody for the Treatment of Breast Cancer,1999, Cancer Biother. Radiopharm. 14: 5-10
✓	CF	Green,MC,etal,Monoclonal antibody therapy for solid tumors,2000,Cancer Treat Rev 26:269-86
✓	CG	Hubert, R.S. et al., STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors, 1999, Pro. Natl Acad. Sci. USA 96: 14523-14528
✓	CH	Knuth, A. et al., Cancer immunotherapy in clinical oncology,2000, Cancer Chemother. Pharmacol. 46, S46-51

EXAMINER: *Amh Wris*

DATE CONSIDERED: *18 January 2007*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO:1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY, DOCKET NO.	2543-1-033
	SERIAL NO.	10/736,227
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT <small>(Use several sheets if necessary)</small>	APPLICANT	Jonathan A. Terrett
	FILING DATE	December 15, 2003
	GROUP	Unknown 1643

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>anu</i>	CI	Lucas S., et al., MAGE-5B, MAGE-B6, MAGE-C2, and MAGE-C3: Four New Members Of The MAGE Family With Tumor-Specific Expression, 2000, Int.J. Cancer 87:55-60
<i>✓</i>	CJ	Miller, K.D., et al., Toward checkmate:biology and breast cancer therapy for the new millennium, 1999, Invest.New Drugs 17: 417-427
	CK	Saffran, D.C., et al., Targget antigens for prostate cancer immunotherapy, 1999, Cancer Metastasis Rev. 18: 437-449
	CL	Shiku, H., et al.,Development of a cancer vaccine: peptides, proteins, and DNA 2000, Cancer Chemother. Pharmacol. 46:S77-82
<i>✓</i>	CM	Stebbing, J., et al.,Herceptin (transtuzamab) in advanced breast cancer, 2000, Cancer Treat. Rev. 26:287-290
<i>✓</i>	CN	Vermeulen, S.J., et al., The α E-catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells, 1999, Oncogene 18: 905-915
	CO	Database EMBL online 1 December 2001(2001-12-01)"NSE2 Protein" Database Accession No. Q96Kn1 XP002234948
EXAMINER: <i>Ann Harris</i>	DATE CONSIDERED: <i>18 January 2007</i>	
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant</small>		